3109-99-7

Basic information

• Product Name: 2-FLUORO-2-METHYL-PROPAN-1-OL
• Synonyms: 2-FLUORO-2-METHYL-PROPAN-1-OL;2-Fluoro-2-Methyl-1-propanol
• CAS NO: 3109-99-7
• Molecular Formula: C₄H₉FO
• Molecular Weight: 92.1120632
• Mol File: 3109-99-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 108-110 °C(Press: 730 Torr)
• Appearance: /
• Density: 0.9681 g/cm3(Temp: 19 °C Press: 20 Torr)
• PKA: 14.57±0.10(Predicted)
• CAS DataBase Reference: 2-FLUORO-2-METHYL-PROPAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-2-METHYL-PROPAN-1-OL(3109-99-7)
• EPA Substance Registry System: 2-FLUORO-2-METHYL-PROPAN-1-OL(3109-99-7)

Safety Data

• Hazardous Substances Data: 3109-99-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 3109-99-7 differently. You can refer to the following data:
1. 2-FLUORO-2-METHYL-PROPAN-1-OLl used as a building block in the preparation of ethers, esters as well as in other organic synthesis.
2. β-fluorinated alcohol used as a building block in the preparation of ethers, esters as well as in other organic synthesis.

Upstream product

• 55816-69-8 ethyl 2-fluoro-isobutyrate 
• 338-76-1 methyl α-fluoro-α-methylpropionate 
• 558-30-5 2-methyl-1,2-epoxypropane 

Downstream Products

• 145349-17-3 (2-fluoro-2-methylpropyl) trifluoromethanesulfonate 

Relevant articles and documents

REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS

Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. The antagonists (such as a hexahydro pyrido[3,4-b]indole, AZD9496, RAD-1901, ARN-810, endoxifen, or fulvestrant) may be an inhibitor of both activating function 1 and activating function 2 of the estrogen receptor. Also provided are combinations of above inhibitors with a secondary agent, which is a CDK 4/6 inhibitor (such as, palbocociclib, ribociclib, abemaciclib, lerociclib, and trilaciclib).

IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS

The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis.

Tricyclic Indazoles - A Novel Class of Selective Estrogen Receptor Degrader Antagonists

Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.